Remibrutinib

Remibrutinib
Clinical data
Trade names	Rhapsido
AHFS/Drugs.com	Monograph
MedlinePlus	a625116
License data	US DailyMed: Remibrutinib;
Routes of; administration	By mouth
ATC code	L04AA60 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name N-[3-[6-Amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide;
CAS Number	1787294-07-8;
PubChem CID	118107483;
IUPHAR/BPS	10457;
DrugBank	DB16852;
ChemSpider	78317000;
UNII	I7MVZ8HDNU;
KEGG	D12285;
ChEMBL	ChEMBL4483575;
PDB ligand	N6Z (PDBe, RCSB PDB);
Chemical and physical data
Formula	C27H27F2N5O3
Molar mass	507.542 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C;
	InChI InChI=1S/C27H27F2N5O3/c1-4-23(35)34(3)9-10-37-25-24(31-14-32-26(25)30)20-12-18(28)13-22(15(20)2)33-27(36)19-8-7-17(11-21(19)29)16-5-6-16/h4,7-8,11-14,16H,1,5-6,9-10H2,2-3H3,(H,33,36)(H2,30,31,32); Key:CUABMPOJOBCXJI-UHFFFAOYSA-N;

Remibrutinib, sold under the brand name Rhapsido, is a medication used for the treatment of chronic spontaneous urticaria.^[1] Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton's tyrosine kinase.^[1] It is taken by mouth.^[1]

Remibrutinib was approved for medical use in the United States in September 2025,^[4] and in the European Union in April 2026.^[2]^[3]

Medical uses

Remibrutinib is indicated for the treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment.^[1]^[2]

Side effects

Common side effects include upper respiratory tract infections, headache, nasopharyngitis, and mild gastrointestinal symptoms such as diarrhea and nausea.^[5]^[6]

Mechanism of action

Remibrutinib is a selective inhibitor of Bruton's tyrosine kinase, a key signaling protein found in mast cells and basophils that regulates their activation and degranulation via pathways involving the FcεRI and B-cell receptor. By irreversibly binding to Bruton's tyrosine kinase, remibrutinib blocks intracellular signaling required for the release of histamine and other inflammatory mediators, thereby reducing the immune cell-driven processes underlying chronic spontaneous urticaria. This mechanism enables suppression of urticaria symptoms upstream from antihistamines, and may also modulate autoimmune activity in some patients.^[6]

Society and culture

Legal status

Remibrutinib was approved for medical use in the United States in September 2025.^[7]

Names

Remibrutinib is the international nonproprietary name.^[8]

Remibrutinib is sold under the brand name Rhapsido.^[7]

References

1 2 3 4 5 "Rhapsido- remibrutinib tablet". DailyMed. 23 March 2026. Retrieved 7 June 2026.
1 2 3 "Rhapsido EPAR". European Medicines Agency (EMA). 27 February 2026. Retrieved 7 June 2026.
1 2 "Rhapsido PI". Union Register of medicinal products. 24 April 2026. Retrieved 7 June 2026.
↑ "Drug Approval Package: Rhapsido". U.S. Food and Drug Administration (FDA). 6 November 2025. Retrieved 7 June 2026.
↑ Burhan M, Ashraf S, Ali A, Shahid I, Ahmed J, Shah MS, et al. (September 2025). "Safety and Efficacy of Remibrutinib for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis". International Archives of Allergy and Immunology: 1–12. doi:10.1159/000548302. PMID 40911497.
1 2 Bożek A, Reich A (May 2025). "Evaluating remibrutinib in the treatment of chronic spontaneous urticaria". Immunotherapy. 17 (7): 479–484. doi:10.1080/1750743X.2025.2510892. PMID 40455080.
1 2 "Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)" (Press release). Novartis Pharmaceuticals. 30 September 2025. Retrieved 1 October 2025 – via PR Newswire.
↑ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

External links

Clinical trial number NCT05030311 for "A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)" at ClinicalTrials.gov
Clinical trial number NCT05032157 for "A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines (REMIX-2)" at ClinicalTrials.gov

[Rhapsido_FDA_label-1] 1 2 3 4 5 "Rhapsido- remibrutinib tablet". DailyMed. 23 March 2026. Retrieved 7 June 2026.

[Rhapsido_EPAR-2] 1 2 3 "Rhapsido EPAR". European Medicines Agency (EMA). 27 February 2026. Retrieved 7 June 2026.

[Rhapsido_PI-3] 1 2 "Rhapsido PI". Union Register of medicinal products. 24 April 2026. Retrieved 7 June 2026.

[4] "Drug Approval Package: Rhapsido". U.S. Food and Drug Administration (FDA). 6 November 2025. Retrieved 7 June 2026.

[Burhan_2025-5] Burhan M, Ashraf S, Ali A, Shahid I, Ahmed J, Shah MS, et al. (September 2025). "Safety and Efficacy of Remibrutinib for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis". International Archives of Allergy and Immunology: 1–12. doi:10.1159/000548302. PMID 40911497.

[Bożek_2025-6] 1 2 Bożek A, Reich A (May 2025). "Evaluating remibrutinib in the treatment of chronic spontaneous urticaria". Immunotherapy. 17 (7): 479–484. doi:10.1080/1750743X.2025.2510892. PMID 40455080.

[Novartis_PR-7] 1 2 "Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)" (Press release). Novartis Pharmaceuticals. 30 September 2025. Retrieved 1 October 2025 – via PR Newswire.

[8] World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]